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Abstract:  CS-1008, a humanized monoclonal antibody that is agonistic to human death receptor 5, was intravenously
administered to cynomolgus monkeys twice a week for 13 weeks at 3 different dose levels (5, 15 and 42 mg/kg) in order
to evaluate its potential toxicity.  A control group received phosphate buffered saline containing 0.01% polysorbate 80.
Each of the 4 groups consisted of 3 male and 3 female cynomolgus monkeys.  No animal in any group died during the
dosing period.  No toxic changes in clinical signs, food consumption, body weight, electrocardiography, ophthalmology,
urinalysis, hematology, blood chemistry, gross pathology, organ weights or histopathology were noted in any group
during the dosing period.  In the toxicokinetic analysis, the values for the maximum concentration of CS-1008 in plasma
and the area under the curve generally increased with increasing dose.  No clear differences in the toxicokinetic
parameters or profiles were observed between the sexes.  Development of anti-CS-1008 antibodies was not detected in
any sample.  The no-observed adverse-effect level (NOAEL) of CS-1008 in cynomolgus monkeys under the conditions
of this study was concluded to be 42 mg/kg in both sexes, when administered intravenously twice a week for 13 weeks.
This study supports the development of CS-1008 as a therapeutic biopharmaceutical. (J Toxicol Pathol 2010; 23: 11–17)
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Introduction
Tumor necrosis factor (TNF)-related apoptosis-
inducing ligand (TRAIL), a member of the TNF superfamily
of cytokines, induces apoptosis in cancer cells in vitro and
has potent anti-tumor activity against tumor xenografts of
various cancers1.  Although TRAIL is not thought to show
cytotoxic effects on normal human hepatocytes, several
published studies suggest potential liver toxicity2–4.  Human
death receptor 5 (DR5, or TRAIL-R2), which is 1 of the 5
receptors for TRAIL, can be detected in human cancers,
including pancreatic, gastric, colon, breast and non-small
cell lung cancer, with low or no expression in normal
tissues5–8.  An agonistic monoclonal antibody (mAb) against
DR5 would be expected to be a therapeutic cancer antibody,
as it preferentially induces apoptosis of tumor cells while
having little or no effect on normal cells.  TRA-8, a murine
anti-DR5 mAb, shows in vitro cytotoxicity in various human
tumor cell lines and in vivo anti-tumor efficacy in murine
xenograft models of human cancer9.  CS-1008 is a
humanized mAb composed of the complementarity
determining regions of TRA-8 and the variable region
framework and constant regions of human immunoglobulin
IgG1.  In previous pharmacologic evaluations, CS-1008
induced cell death in various DR5-expressing human tumor
cell lines, without inducing cell death of human primary
hepatocytes10.
The objective of this study was to investigate the
potential toxicity of CS-1008 following 13 weeks of
intravenous dosing in a relevant animal species.
Materials and Methods
Animals
In order to determine a relevant animal species for
toxicologic assessment, the following investigations were
conducted in accordance with the 1997 International
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guidelines.  Analysis of the cDNA sequence of cynomolgus-
monkey DR5, measurement of the binding affinity of CS-
1008 to human and cynomolgus-monkey DR5, cross-
reactivity survey of CS-1008 immunohistochemical staining
in human and cynomolgus-monkey tissues and confirmation
of the functional pathway for DR5-mediated apoptosis in a
monkey-cell line were all performed.  The cDNA sequences
of monkey DR5 were similar to those of human DR5.  Based
on comparative binding kinetics of CS-1008 to human and
cynomolgus monkey DR5, CS-1008 can be considered to
have similar affinities for human DR5 and monkey DR5.
Cross-reactivity testing demonstrated
immunohistochemical-staining similarities between normal
human and cynomolgus monkey tissues.  In addition, the
pharmacological activity observed in a cynomolgus
monkey-derived cell line that expresses DR5 suggests that
the mechanism for CS-1008-mediated cell-death induction is
functioning.  The results indicated that the cynomolgus
monkey is a relevant animal species for toxicology
assessment for this study.
In this study, 12 male and 12 female purpose-bred
cynomolgus monkeys (Macaca fascicularis), aged 3–5 years
and weighing 2.4–3.9 kg at the initiation of dosing, were
purchased from Guangdong Scientific Instruments &
Materials Import / Export Corporation (Guangzhou, China)
and used.  The monkeys were randomly assigned to 1 of 4
groups in order to achieve approximately equal mean body
weights among the groups.  The animals were housed
individually in stainless steel cages residing in a room
maintained at 24.4–27.5°C with 45–67% relative humidity
and a 12-hour light and dark cycle.  Harlan Teklad Global
Certified 25% Protein Primate Diet (Harlan Sprague Dawley
Inc.) was provided once daily to each animal in the
afternoon.  Water was available ad libitum from an
automatic supply.  This study was approved by the
Institutional Animal Care and Use Committee of Shin
Nippon Biomedical Laboratories, Ltd.
CS-1008 and control
CS-1008 in a concentration of 10.60 mg/mL in
phosphate buffered saline (PBS) containing 0.01%
polysorbate 80 was prepared in-house and stored at or below
–70°C until use.  As the control, PBS containing 0.01%
polysorbate 80 was also prepared and stored in the same
manner.  CS-1008 was returned to room temperature prior to
use.  The control was thawed under running water and
returned to room temperature prior to use.
Treatment
Twice a week for 13 weeks, 1 of 3 dose levels of CS-
1008 (5, 15 or 42 mg/kg; 0.47, 1.42 or 4 mL/kg) or the
control (PBS containing 0.01% polysorbate 80, 4 mL/kg)
was administered in accordance with the dosing group to
which the animal had been assigned.  Each group consisted
of 3 male and 3 female cynomolgus monkeys.  The CS-1008
or control was intravenously injected into the cephalic vein
of the forearm at an injection rate of 5 mL/min using a
disposable syringe and either a needle or an indwelling
needle.  The highest dose level was set by taking into
account the concentration of CS-1008 and the maximum
feasible dose volume.  The lower dose levels were set in a
geometric ratio of approximately 3.
Clinical evaluations
Clinical signs of all the animals were observed 3 times
daily on the dosing days, once daily on non-dosing days and
once on the day of gross pathology.  Food consumption of all
animals was recorded daily and was ascertained from the
amount of food supplied to each animal and the amount
remaining.  For each week, the mean value consumed per
day was taken as the daily food consumption.  All animals
were weighed using an electronic balance (HP-40K, A&D
Company, Limited) twice during the acclimation period,
once weekly after initiation of dosing and once on the day of
gross pathology.  Electrocardiograms were recorded without
anesthesia using an electrocardiograph system for animals
(Cardisuny α6000AX-D, Fukuda M-E Kogyo Co., Ltd.) by
the standard lead method before initiation of dosing (time
corresponding to approximately 1 hour after administration)
and approximately 1 hour after administration at Week 13 of
dosing.  Heart rate, PR interval, QRS duration, QT interval
and QTc from the wave of lead II were measured.
Ophthalmologic examinations were performed under
ketamine hydrochloride anesthesia (Fuji, approximately 10
mg/kg, Fuji Chemical Industry Co., Ltd.) by intramuscular
injection before initiation of dosing and after administration
at Week 13 of dosing.  The optic media and ocular fundus
were observed after instillation of a mydriatic drug
(Mydrin®-P, Santen Pharmaceutical Co., Ltd.).  The anterior
portion of the eye and the optic media were examined
visually using a penlight and slit lamp (SL-14, Kowa Co.,
Ltd.).  The ocular fundus was examined using an indirect
ophthalmoscope (Genesis, Kowa Co., Ltd.).
Clinical laboratory tests
Blood was drawn from the femoral vein before
initiation of dosing and once at Weeks 4, 8 and 13 of dosing
with a syringe containing 3.8% weight/volume (w/v) sodium
citrate solution as an anticoagulant.  Plasma was obtained by
centrifugation, and coagulation parameters were measured
using an automatic blood coagulation-measuring apparatus
(CA-5000, Sysmex Corporation).  For measurement of other
hematologic parameters, whole blood was drawn with a
syringe and treated with an anticoagulant (EDTA-2K).
Blood smears were prepared for measurement of differential
leukocytes.  The hematologic parameters were measured
using a hematology system (ADVIA120, Bayer Diagnostics
Manufacturing Ltd.).  In addition, blood was drawn from the
femoral vein and left at room temperature for 20–60 minutes.
Serum was obtained by centrifugation, and blood-chemistry
parameters were measured with an automatic analyzer (JCA-
BM8, JEOL Co., Ltd.).  Urinalysis was performed beforeKimotsuki, Tanaka, Sugiura et al. 13
initiation of dosing and after administration at Week 13 of
dosing.  Urine samples at 2 hours and 16 hours were
collected in a metabolic cage.  Color, pH, glucose, ketone
bodies, bilirubin, occult blood, urobilinogen, protein and
sediments in fresh urine were evaluated using an automatic
urine analyzer (Clinitek 200+, Miles Labs., Inc.) or an
automated urine quantitative analyzer (UM-3410, Arkray
Factory, Inc.).  Urine volume, specific gravity, N-Acetyl-
beta-D-glucosaminidase activity, and osmolarity in 16-hour
preserved urine were also evaluated using a measuring
cylinder, a urinary refractometer (URICON-JE, Atago Co.,
Ltd.), a spectrophotometer (U-3200, Hitachi, Ltd.) or a fully
Automated Osmotic Pressure Meter OM-6050
(OsmostationTM, Arkray Factory, Inc.).
Pathology
At the end of the dosing period, all animals were
weighed and euthanized by exsanguination under anesthesia
by an intravenous injection of sodium pentobarbital solution
(Tokyo Kasei Kogyo Co., Ltd.) into the tail vein.  External
appearance, internal organs and tissues were observed
macroscopically.  Organs were weighed using an electronic
balance (HR-200 and HF-3000, A&D Company, Limited).
Relative organ weights were calculated from the body
weight on the day of gross pathology.  In the case of bilateral
organs weighed separately, the total bilateral weight was
calculated.  The organs and tissues were fixed in 10% neutral
buffered formalin.  The eyeballs and optic nerves were fixed
in a solution of formaldehyde and glutaraldehyde, and the
testes were fixed in Bouin’s solution.  The organs and tissues
were embedded in paraffin and sectioned.  The paraffin
sections were hematoxylin-eosin-stained and examined
microscopically.
Toxicokinetics
Blood was drawn from the femoral vein with a syringe
containing sodium heparin before administration of CS-1008
or the control and 1, 7, 24 and 72 hours after administration
on Day 1; 72 hours after administration at Weeks 4 and 8;
and before administration and 1, 7, 24 and 96 hours after
administration at Week 13.  The samples were immediately
centrifuged to obtain plasma.  The plasma obtained was
stored in a freezer.  The plasma concentrations of CS-1008
were measured using an enzyme-linked immunosorbent
assay (ELISA), and the toxicokinetic parameters were
calculated.
Anti-CS-1008 antibody titer measurement in plasma
Blood was drawn from the femoral vein with a syringe
containing sodium heparin on Day 1 of dosing, 72 hours
after administration at Weeks 4 and 8 of dosing and 96 hours
after administration on the final dosing day (the day of gross
pathology).  The samples were immediately centrifuged to
obtain plasma.  The plasma obtained was frozen.  The
plasma concentrations of anti-CS-1008 antibody were
determined using an ELISA method.
Statistical analysis
Data on food consumption, body weight,
electrocardiography, urinalysis, hematology, blood
chemistry and organ weights were first analyzed for
homogeneity of variance by Bartlett’s test.  If the variance
was homogeneous, Dunnett’s test was applied to compare
the means of the CS-1008 groups with that of the control
group.  If the variance was heterogeneous by Bartlett’s test,
a non-parametric Dunnett’s test was applied to compare the
mean ranks of the CS-1008 groups with that of the control
group.  Data from clinical signs, ophthalmology, urinalysis
(except for quantitative data), gross pathology and
histopathology were not analyzed statistically.
Results
No animals died, and no abnormalities were observed
in any group during the dosing period in terms of clinical
signs, food consumption or body weight (Fig. 1).  In
electrocardiography, no abnormal waveforms were noted in
any group, and no CS-1008-related changes were noted in
the heart rate, PR interval, QRS duration, QT interval or
QTc.  No CS-1008-related abnormalities were noted in any
group at Week 13 of dosing in the ophthalmologic
examination.  In addition, no test article-related changes
were noted in any group during the dosing period in the
urinalysis or the hematologic examination (Table 1).
Blood-chemical examinations revealed no CS-1008-
related changes in any group throughout the dosing period
(Table 2).  When compared with the control group, a high
bilirubin level was noted in male monkeys in the 42 mg/kg
group at Week 13 of dosing.  However, this change was
judged unrelated to CS-1008 administration as there were no
differences from the pre-dosing values.  No changes were
seen in any group for the serum liver enzymes including
aspartate aminotransferase (AST), alanine aminotransferase
(ALT), alkaline phosphatase, and lactate dehydrogenase.
Low blood urea nitrogen was noted in males in the 5 mg/kg
group at Week 13 of dosing; however, this change was
judged unrelated to the test article since the individual values
were within the range of the background data.
No CS-1008-related changes were noted in any group at
the end of the dosing period in the organ weight
measurements (Table 3).  When compared with the control
group, low kidney weights were noted in females in the 5
and 15 mg/kg groups; however, these changes were judged
toxicologically insignificant since they were not dose-
related, and the individual values were within the range of
the background data.  In regard to gross pathology, no CS-
1008-related changes were noted in any organ in any group
at the end of the dosing period.  Histopathology revealed
glomerulosclerosis with thickening of the Bowman’s
capsule, regeneration of tubules and interstitial fibrosis in the
kidneys in 1 male from the 42 mg/kg group; however, these
changes were judged toxicologically insignificant as they
were unilateral and focal.  No CS-1008-related changes
including apoptotic bodies were found in the liver.14 Toxicity Study of  CS-1008 in Cynomolgus Monkeys
Fig. 1. Body weights of cynomolgus monkeys (males, left panel; females, right panel) treated for 13 weeks with 1 of
3 doses of CS-1008 (5, 15 or 42 mg/kg) or phosphate buffered saline (PBS) containing 0.01% polysorbate 80.
Table 1. Primary Hematology Parameters in Cynomolgus Monkeys Treated with CS-1008 or Phosphate Buffered Saline Containing 0.01%
Polysorbate 80 (Control)
Parameter Sex Time of analysis Control CS-1008 dose (mg/kg)
51 54 2
Red blood cell count Male Before dosing 5.62 ± 0.48 6.08 ± 0.16 5.15 ± 0.38 5.89 ± 0.36
(× 106/mm3) Week 4 5.24 ± 0.38 5.92 ± 0.11 5.03 ± 0.43 5.50 ± 0.43
Week 8 5.27 ± 0.29 5.96 ± 0.25 5.14 ± 0.44 5.45 ± 0.42
Week 13 5.30 ± 0.20 6.02 ± 0.13 5.31 ± 0.54 5.66 ± 0.38
Female Before dosing 5.43 ± 0.28 5.16 ± 0.05 5.12 ± 0.50 5.82 ± 0.36
Week 4 5.43 ± 0.18 5.02 ± 0.09 5.03 ± 0.32 5.41 ± 0.24
Week 8 5.28 ± 0.15 4.79a) ± 0.04 5.11 ± 0.11 5.31 ± 0.16
Week 13 5.51 ± 0.21 5.06 ± 0.17 5.49 ± 0.02 5.56 ± 0.39
White blood cell count Male Before dosing 14.98 ± 5.66 14.58 ± 6.69 8.93 ± 2.05 17.68 ± 7.26
(× 103/mm3) Week 4 13.73 ± 4.12 12.81 ± 6.12 8.39 ± 1.87 12.02 ± 6.50
Week 8 15.13 ± 3.99 14.82 ± 5.54 10.56 ± 2.69 11.63 ± 5.55
Week 13 14.91 ± 2.42 14.80 ± 7.05 11.83 ± 2.82 10.88 ± 1.44
Female Before dosing 11.04 ± 1.61 13.44 ± 6.37 8.98 ± 1.82 12.40 ± 2.36
Week 4 11.88 ± 1.68 12.11 ± 6.50 8.36 ± 1.90 11.75 ± 4.35
Week 8 13.29 ± 0.63 12.42 ± 6.24 8.39 ± 1.83 11.76 ± 3.97
Week 13 11.55 ± 0.91 11.84 ± 5.41 10.89 ± 1.77 12.46 ± 4.48
Lymphocyte count Male Before dosing 11.72 ± 5.34 11.12 ± 6.43 5.19 ± 1.07 12.06 ± 6.31
(× 103/mm3) Week 4 10.73 ± 3.68 10.14 ± 5.67 5.15 ± 1.16 6.38 ± 2.19
Week 8 11.72 ± 3.16 11.83 ± 5.87 6.12 ± 1.14 7.46 ± 2.05
Week 13 11.16 ± 2.94 11.85 ± 6.39 7.39 ± 1.30 7.89 ± 0.72
Female Before dosing 7.71 ± 1.86 8.57 ± 4.02 5.64 ± 0.90 7.32 ± 2.57
Week 4 8.01 ± 1.04 8.11 ± 4.26 5.29 ± 0.42 6.57 ± 3.28
Week 8 9.92 ± 1.09 8.31 ± 4.59 5.50 ± 1.41 7.42 ± 3.14
Week 13 8.97 ± 1.24 8.10 ± 3.74 6.92 ± 1.31 7.86 ± 3.63
Neutrophil count Male Before dosing 2.44 ± 1.25 2.79 ± 0.68 3.16 ± 1.54 4.77 ± 3.14
(× 103/mm3) Week 4 2.26 ± 0.82 2.08 ± 0.29 2.65 ± 1.84 5.10 ± 4.30
Week 8 2.74 ± 1.05 3.02 ± 0.69 3.65 ± 2.37 3.59 ± 3.45
Week 13 2.97 ± 1.53 2.26 ± 0.62 3.80 ± 2.19 2.41 ± 0.76
Female Before dosing 2.75 ± 1.53 4.04 ± 2.48 2.86 ± 0.81 4.43 ± 0.42
Week 4 3.18 ± 1.23 3.30 ± 1.95 2.64 ± 1.49 4.65 ± 1.31
Week 8 2.48 ± 1.77 3.41 ± 1.45 2.48 ± 0.67 3.78 ± 0.63
Week 13 2.01 ± 0.54 3.07 ± 1.48 3.46 ± 0.91 4.02 ± 0.63
All values given as means ± standard deviation.
a): Significantly different from the control group at P<0.01 compared with control.Kimotsuki, Tanaka, Sugiura et al. 15
Table 2. Primary Blood-Chemistry Parameters in Cynomolgus Monkeys Treated with CS-1008 or Phosphate Buffered Saline Containing 0.01%
Polysorbate 80 (Control)
Parameter Sex Time of analysis Control CS-1008 dose (mg/kg)
51 54 2
AST Male Before  dosing 26 ± 82 6 ± 73 0 ± 82 5 ± 8
(IU/L) Week 4 23 ± 52 7 ± 53 1 ± 13 33 ± 22
Week 8 28 ± 11 24 ± 13 0 ± 92 3 ± 4
Week 13 23 ± 32 2 ± 32 7 ± 62 3 ± 7
Female Before dosing 21 ± 12 5 ± 63 3 ± 82 9 ± 6
Week 4 21 ± 22 5 ± 83 9 ± 13 28 ± 14
Week 8 28 ± 72 7 ± 43 2 ± 12 32 ± 18
Week 13 22 ± 52 4 ± 72 4 ± 72 5 ± 11
ALT Male Before  dosing 26 ± 11 32 ± 20 36 ± 13 27 ± 10
(IU/L) Week  4 28 ± 14 21 ± 64 1 ± 21 24 ± 6
Week 8 32 ± 15 23 ± 53 6 ± 14 26 ± 8
Week 13 28 ± 12 20 ± 73 6 ± 14 23 ± 6
Female Before dosing 35 ± 44 0 ± 27 49 ± 22 81 ± 48
Week 4 37 ± 42 2 ± 37 2 ± 52 67 ± 45
Week 8 48 ± 15 47 ± 18 64 ± 50 69 ± 48
Week 13 36 ± 81 9 ± 33 5 ± 13 40 ± 32
ALP Male Before  dosing 1387 ± 207 1302 ± 237 1210 ± 469 1476 ± 284
(IU/L) Week 4 1326 ± 295 1291 ± 315 1302 ± 212 1535 ± 294
Week 8 1307 ± 295 1275 ± 291 1304 ± 192 1420 ± 169
Week 13 1300 ± 327 1272 ± 202 1363 ± 163 1435 ± 135
Female Before dosing 772 ± 308 593 ± 161 410 ± 140 632 ± 311
Week 4 833 ± 210 588 ± 109 452 ± 205 601 ± 334
Week 8 774 ± 229 508 ± 85 468 ± 196 563 ± 290
Week 13 772 ± 110 580 ± 156 457 ± 179 546 ± 234
LDH Male Before  dosing 556 ± 252 549 ± 158.9 510 ± 43 522 ± 29
(IU/L) Week  4 721 ± 221 693 ± 232.6 596 ± 200 872 ± 623
Week 8 966 ± 723 514 ± 70.6 611 ± 110 590 ± 145
Week 13 730 ± 57 545 ± 119.1 549 ± 134 727 ± 276
Female Before dosing 379 ± 88 420 ± 132.9 524 ± 207 390 ± 29
Week 4 425 ± 72 624 ± 316.7 626 ± 49 410 ± 102
Week 8 699 ± 223 676 ± 285.1 486 ± 84 403 ± 56
Week 13 541 ± 230 748 ± 546.2 404 ± 99 440 ± 110
Total bilirubin  Male Before dosing 0.20 ± 0.03 0.19 ± 0.04 0.20 ± 0.03 0.28 ± 0.02
(mg/dL) Week 4 0.20 ± 0.05 0.21 ± 0.02 0.20 ± 0.02 0.30 ± 0.13
Week 8 0.21 ± 0.05 0.20 ± 0.02 0.19 ± 0.02 0.27 ± 0.01
Week 13 0.18 ± 0.04 0.18 ± 0.01 0.21 ± 0.02 0.26a) ± 0.04
Female Before dosing 0.16 ± 0.01 0.19 ± 0.08 0.22 ± 0.09 0.18 ± 0.05
Week 4 0.17 ± 0.05 0.20 ± 0.08 0.27 ± 0.12 0.19 ± 0.05
Week 8 0.18 ± 0.06 0.22 ± 0.04 0.23 ± 0.06 0.21 ± 0.03
Week 13 0.16 ± 0.02 0.22 ± 0.05 0.19 ± 0.03 0.18 ± 0.03
BUN Male Before  dosing 23.1 ± 2.8 19.9 ± 5.4 23.8 ± 6.7 21.8 ± 4.5
(mg/dL) Week  4 26.3 ± 7.3 19.5 ± 3.7 23.7 ± 5.1 21.5 ± 1.7
Week 8 28.2 ± 4.6 20.7 ± 4.2 24.8 ± 5.0 22.2 ± 0.5
Week 13 29.8 ± 4.6 20.5a) ± 3.3 23.7 ± 4.3 23.2 ± 0.9
Female Before dosing 17.5 ± 3.5 21.9 ± 8.5 19.0 ± 5.9 18.1 ± 4.0
Week 4 20.7 ± 4.3 21.6 ± 3.4 22.0 ± 4.1 19.7 ± 4.5
Week 8 20.9 ± 5.3 21.1 ± 2.6 23.4 ± 2.2 22.0 ± 8.0
Week 13 20.9 ± 2.7 19.8 ± 5.0 23.7 ± 1.0 20.6 ± 6.1
Creatinine Male Before dosing 0.67 ± 0.12 0.69 ± 0.02 0.61 ± 0.02 0.53 ± 0.02
(mg/dL) Week  4 0.60 ± 0.81 0.67 ± 0.04 0.64 ± 0.07 0.60 ± 0.06
Week 8 0.62 ± 0.09 0.68 ± 0.02 0.61 ± 0.03 0.60 ± 0.06
Week 13 0.64 ± 0.09 0.70 ± 0.04 0.68 ± 0.05 0.65 ± 0.03
Female Before dosing 0.51 ± 0.06 0.62 ± 0.07 0.53 ± 0.05 0.58 ± 0.03
Week 4 0.50 ± 0.08 0.59 ± 0.12 0.53 ± 0.03 0.59 ± 0.05
Week 8 0.48 ± 0.03 0.60 ± 0.10 0.54 ± 0.10 0.56 ± 0.05
Week 13 0.50 ± 0.08 0.61 ± 0.14 0.54 ± 0.10 0.59 ± 0.07
All values given as means ± standard deviation. ALP: alkaline phosphatase.  ALT: alanine aminotransferase.  AST: aspartate aminotransferase.
BUN: blood urea nitrogen.  LDH: lactate dehydrogenase.  a): Significantly different from the control group at P<0.05.   16 Toxicity Study of  CS-1008 in Cynomolgus Monkeys
In the toxicokinetic analysis, the values for the
maximum concentration of CS-1008 in plasma (Cmax) and
the area under the curve (AUC) generally increased with
dose (Table 4).  The trough plasma concentrations markedly
increased at Week 4 compared with Day 1 at all doses;
however, the ratio increase after Week 4 was much lower
than that seen at Week 4 (Table 5).  The profiles of the
trough plasma concentrations suggest that the toxicokinetic
parameters had almost reached a steady state by Week 4.
There were no clear differences between the sexes in terms
of the toxicokinetic parameters or profiles.  The anti-CS-
1008 antibody concentration obtained for each plasma
sample was below the lower limit of quantification (0.2 μg/
mL).
Table 3. Primary Organ Weights at the End of the Dosing Period in Cynomolgus Monkeys Treated with CS-1008 or Phosphate
Buffered Saline Containing 0.01% Polysorbate 80 (Control)
Organ weight (g) Sex Control CS-1008 dose (mg/kg)
51 5 4 2
Liver Male 74.6 ± 12.8 59.5 ± 8.5 70.2 ± 9.4 76.5 ± 2.5
Female 65.8 ± 12.7 53.0 ± 6.0 54.2 ± 4.7 55.8 ± 7.0
Kidneya) Male 14.5 ± 2.0 13.7 ± 1.3 17.1 ± 2.3 16.9 ± 1.5
Female 13.4 ± 1.9 10.8b) ± 0.6 10.4b) ± 0.4 12.0 ± 0.6
Spleen Male 6.2 ± 2.4 3.6 ± 1.0 4.0 ± 0.9 7.0 ± 1.6
Female 5.4 ± 2.0 2.8 ± 0.5 2.7 ± 0.2 4.0 ± 0.7
Thymus Male 5.4 ± 1.7 3.7 ± 1.7 3.9 ± 1.9 2.9 ± 0.3
Female 3.0 ± 1.6 2.1 ± 0.5 2.6 ± 1.0 2.2 ± 1.1
All values given as means ± standard deviation.   a): The sum of the right and left kidneys.  b): Significantly different from the
control group at P<0.05.  
Table 4. Toxicokinetic Parameters in Cynomolgus Monkeys Treated with CS-1008
Time of  Parameter Sex CS-1008 dose (mg/kg)
analysis 5 15 42
Day 1  Cmax (μg/mL) Male 135.0 ± 15.4 333.2 ± 7.2 1124.0 ± 172.0
Female 124.1 ± 22.1 430.3 ± 31.9 1067.3 ± 56.1
AUC0–3d (μg•day/mL) Male 245 ± 13.0 728 ± 27.2 2300 ± 281
Female 262 ± 34.4 929 ± 106 2280 ± 167
Week 13  Cmax (μg/mL) Male 731.7 ± 132.0 1763.0 ± 142.0 4754.7 ± 383.0
Female 783.0 ± 59.7 2174.0 ± 230.6 5523.7 ± 1207.9
AUC0–3d (μg•day/mL) Male 2630 ± 311 5560 ± 505 15500 ± 1560
Female 2260 ± 295 7210 ± 936 17600 ± 3430
All values given as means ± standard deviation. Cmax: maximum concentration of CS-1008 in plasma.  AUC0–3d: area under the curve
(of the plot of the concentration of CS-1008 in plasma vs. time) for 3 days.
Table 5. Trough Plasma Concentrations of CS-1008 (μg/mL) in Cynomolgus Monkeys Treated with CS-1008
Sex Time of analysis CS-1008 dose (mg/kg)
51 5 4 2
Male Week 1 (72 h after 1st dosing) 64.30 ± 3.58 204.0 ± 5.6 540.3 ± 40.1
Week 4 (72 h after 7th dosing) 410.3 ± 32.7 1002.3 ± 43.0 2508.7 ± 200.8
Week 8 (72 h after 15th dosing) 494.0 ± 10.5 1349.7 ± 181.1 2990.0 ± 202.9
Week 13 (72 h after 25th dosing) 639.0 ± 90.4 1487.0 ± 200.7 3810.0 ± 397.5
Week 13 (96 h after 26th dosing) 660.7 ± 66.8 1342.0 ± 185.7 3727.7 ± 392.2
Female Week 1 (72 h after 1st dosing) 67.03 ± 9.61 238.7 ± 27.6 632.0 ± 50.9
Week 4 (72 h after 7th dosing) 297.7 ± 166.9 1262.3 ± 120.8 2972.7 ± 273.4
Week 8 (72 h after 15th dosing) 374.3 ± 111.0 1597.0 ± 202.2 3640.3 ± 572.9
Week 13 (72 h after 25th dosing) 540.7 ± 53.3 1680.7 ± 338.5 4539.3 ± 1132.9
Week 13 (96 h after 26th dosing) 503.7 ± 72.2 1725.3 ± 286.7 4205.0 ± 931.4
All values given as means ± standard deviation. Kimotsuki, Tanaka, Sugiura et al. 17
Discussion
TRAIL-induced apoptosis has been seen in many tumor
cells but not in normal cells in vivo11.  The TRAIL receptors
are attractive targets for cancer treatment.  Agonistic
antibodies against TRAIL-R1 (DR4) and TRAIL-R2 (DR5)
are currently in preclinical or clinical studies12.  Current
evidence suggests that some of these antibodies might
potentially be toxic to the liver.  An agonistic anti-mouse
DR5 mAb treatment has been reported to induce cholangitis
and cholestatic liver injury in C57BL/6 mice13.  In a phase 1
clinical trial of mapatumumab (HGS-ETR1, a fully human
mAb against TRAIL-R1), two patients receiving 10 mg/kg
every 14 days had elevated results of liver function tests14.
Grade 3 elevation of ALT and grade 2 elevation of AST were
noted in a patient given a single dose of Apomab (a fully
human mAb against TRAIL-R2) at a dose of 10 mg/kg in a
phase 1 study15.  In two patients treated with lexatumumab
(HGS-ETR2, a fully human mAb against TRAIL-R2) at 20
mg/kg, grade 4 elevations of AST and ALT and grade 3
hyperbilirubinemia were noted in a phase 1 study16.
Meanwhile, TRA-8, a murine anti-DR5 mAb, and CS-1008,
a humanized mAb composed of the complementarity
determining regions of TRA-8, do not appear to induce cell
death in human primary hepatocytes9, 10.  In the present
study, it was confirmed that CS-1008 did not induce toxic
changes in any tissues or organs, including the liver, in
cynomolgus monkeys.  Based on the results of the present
study, the no-observed adverse-effect level (NOAEL) of CS-
1008 in cynomolgus monkeys of both sexes was concluded
to be 42 mg/kg when administered intravenously twice a
week for 13 weeks.  These safety profiles support the
development of CS-1008 as a therapeutic
biopharmaceutical.
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